These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25023882)

  • 21. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
    Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
    Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
    Fujimoto K; Hamamoto Y; Honjo S; Kawasaki Y; Mori K; Tatsuoka H; Matsuoka A; Wada Y; Ikeda H; Fujikawa J; Koshiyama H
    Diabetes Res Clin Pract; 2013 Feb; 99(2):e21-3. PubMed ID: 23228390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Is there a need of glitazones in the treatment of diabetes?].
    Halse J
    Tidsskr Nor Laegeforen; 2007 Aug; 127(16):2124; author reply 2124. PubMed ID: 17717584
    [No Abstract]   [Full Text] [Related]  

  • 26. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
    Tseng CH; Huang TS
    Diabetes Res Clin Pract; 2005 Nov; 70(2):193-4. PubMed ID: 16188579
    [No Abstract]   [Full Text] [Related]  

  • 27. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
    Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
    Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pioglitazone and oral cancer risk in patients with type 2 diabetes.
    Tseng CH
    Oral Oncol; 2014 Feb; 50(2):98-103. PubMed ID: 24239280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes.
    Tseng CH
    Metabolism; 2014 Aug; 63(8):1049-55. PubMed ID: 24889868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Kidney and glitazones].
    Deray G; Izzedine H; Launay-Vacher V; Bagnis C
    Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S81-90. PubMed ID: 15959407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Glitazones--again].
    Halse J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2707; author reply 2707. PubMed ID: 17952161
    [No Abstract]   [Full Text] [Related]  

  • 32. Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.
    Anan F; Masaki T; Fukunaga N; Teshima Y; Iwao T; Kaneda K; Umeno Y; Okada K; Wakasugi K; Yonemochi H; Eshima N; Saikawa T; Yoshimatsu H
    Eur J Clin Invest; 2007 Sep; 37(9):709-14. PubMed ID: 17696960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The true place of glitazones in the treatment of diabetes: after the PROactive study].
    Lindberg M; Jørgensen PH; Kampmann JP
    Ugeskr Laeger; 2006 Jun; 168(25):2477-9; author reply 2479-80. PubMed ID: 16824389
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk of fractures with glitazones: a critical review of the evidence to date.
    Bodmer M; Meier C; Kraenzlin ME; Meier CR
    Drug Saf; 2009; 32(7):539-47. PubMed ID: 19530741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.
    Al-Azzam SI; Alomari M; Khader YS; Almahasneh FA; Muflih SM; Altawalbeh S
    Endocr Res; 2012; 37(1):7-11. PubMed ID: 21977974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glitazones in type 2 diabetes--documented risks, uncertain benefits].
    Håkansson J
    Lakartidningen; 2007 Oct 24-30; 104(43):3198-200. PubMed ID: 18018937
    [No Abstract]   [Full Text] [Related]  

  • 37. Are the adverse effects of glitazones linked to induced testosterone deficiency?
    Carruthers M; Trinick TR; Jankowska E; Traish AM
    Cardiovasc Diabetol; 2008 Oct; 7():30. PubMed ID: 18922158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Which should we ADOPT: sulphonylureas or glitazones?
    Koshiyama H; Inagaki N; Seino Y
    Diabet Med; 2007 Jul; 24(7):804. PubMed ID: 17596243
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring?
    El-Muayed M; Lavis VR; Safi HJ; Fuentes F
    Am J Cardiol; 2004 Mar; 93(5):600-2. PubMed ID: 14996586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.